Ipertrofan (Mepartricin)

Mepartricin belongs to the macrolide class of antibiotics. It binds to the bacterial 50S ribosomal subunit, inhibiting protein synthesis, which limits bacterial growth. Additionally, it modulates the immune response by decreasing pro‑inflammatory cytokines, providing anti‑inflammatory benefits in affected tissues.

The dosage of Ipertrofan is determined by the prescribing healthcare professional based on the patient’s condition, severity, and response to therapy. Patients should follow the exact regimen provided by their prescriber and not adjust the dose on their own.

Safety data for Mepartricin in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers should discuss individual risks and benefits with the patient.

To request Ipertrofan, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Ipertrofan (Mepartricin) offers both antibacterial and anti‑inflammatory actions, whereas many standard antibiotics target only bacterial eradication. Compared with fluoroquinolones, Mepartricin may have a lower risk of tendon toxicity but shares similar gastrointestinal side‑effect profiles. Choice of therapy depends on microbial susceptibility and patient tolerance.

Ipertrofan tablets should be stored below 25 °C in a dry place. Keep the product in its original packaging to protect it from moisture and light. Do not store in bathrooms or near heat sources, and keep out of reach of children.

Ipertrofan is taken orally, usually with a full glass of water. It can be taken with or without food, but consistent administration with respect to meals helps maintain stable absorption. Patients should swallow the tablet whole and not crush or chew it unless directed by a healthcare professional.

Serious risks include severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome, hepatic dysfunction, and marked neutropenia. Patients should seek immediate medical attention if they experience rash, fever, jaundice, persistent vomiting, or signs of infection while on therapy.

Ipertrofan should be avoided in individuals with a known hypersensitivity to Mepartricin or other macrolide antibiotics. Patients with severe liver impairment, significant QT‑interval prolongation, or those taking contraindicated medications should not use this product without close medical supervision.